US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Virtus LifeSci Biotech Clinical Trials ETF

53.66

+0.74111.40%

Volume:9K

Turnover:493.48K

Market Cap:50.97M

PE:- -

High:54.55

Open:54.55

Low:52.64

Close:52.91

52wk High:56.18

52wk Low:22.83

Shares:950.00K

Float Shares:950.00K

Volume Ratio:0.40

T/O Rate:0.98%

Dividend:0.65

Dividend Rate:1.22%

ROE:--

ROA:--

PB:1.15

PE(LYR):- -

Loading ...

Overview Company News Filings

TheraCryf raises £1.05m to advance addiction drug towards Phase 1 trials

Moderna Stock (MRNA) Soars 133%; Five-Star William Blair Analyst Says Strong Cancer Data Could Be a Game-Changer

Cullinan, Taiho say results of Phase 3 trial selected for presentation

Biodexa recruits 87 of 168 subjects in Serenta Phase 3 eRapa polyposis trial

Video: Moderna skyrockets after cancer vaccine shows promise in Phase 3 trial

Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP

Patent Cliffs Drive Pharma Expansion as Biotech M&A and IPO Markets Stage a Comeback

Vivoryon Sets Date for 2026 AGM as Kidney Disease Program Advances

Amylyx announces Lucidity Phase 3 trial met primary endpoint

argenx’s VYVGART Hytrulo hits Phase 3 myositis goal in high‑need IMNM and DM

Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial

Mesoblast Reaches Pivotal Phase 3 Milestone in Chronic Back Pain Trial

BNK Banking Corp Confirms CEO and CFO in Permanent Roles

Xencor Advances Dual-Antibody Cancer Trial, Keeping Investor Focus on XNCR

BofA Securities Boosts Targets on Chinese CXO Players as Strong Biotech Funding Fuels R&D

Bank of America Securities Raises Targets for Chinese CXO Firms on Strong Biotech Funding

Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates

NeuroThera Labs Wins Japanese Patent for Next-Generation Pain and Fever Therapy

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Youcare Pharmaceutical Subsidiary Receives U.S. FDA Clearance for YKYY033 Injection Clinical Trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/BBC/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BBC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBC\",,,,,undefined,":{"symbol":"BBC","market":"US","secType":"STK","nameCN":"Virtus LifeSci Biotech Clinical Trials ETF","latestPrice":53.655,"timestamp":1788379093771,"preClose":52.9139,"halted":0,"volume":9263,"delay":0,"changeRate":0.014005771640344087,"floatShares":950000,"shares":950000,"eps":0,"marketStatus":"Trading","change":0.7411,"latestTime":"09-02 15:58:14 EDT","open":54.5499,"high":54.5499,"low":52.64,"amount":493482.277069,"amplitude":0.036094,"askPrice":54.26,"askSize":500,"bidPrice":53.21,"bidSize":400,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788379200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":52.9139,"sharesOutstanding":900004,"nav":52.968,"aum":50319973.84,"dividendRate":0.012161,"bidAskSpread":0.002379,"postHourTrading":{"tag":"盘后","latestPrice":52.91,"preClose":52.9139,"latestTime":"19:30 EDT","volume":23,"amount":1218.3912,"timestamp":1788305405716,"change":-0.0039,"changeRate":-0.000074,"amplitude":0},"volumeRatio":0.397497,"impliedVol":0.3646,"impliedVolPercentile":0.7937},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBC\",,,,,undefined,":{"symbol":"BBC","floatShares":950000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.397497,"shares":950000,"dividePrice":0.6525,"high":54.5499,"amplitude":0.036094,"preClose":52.9139,"low":52.64,"week52Low":22.825,"pbRate":"1.15","week52High":56.18,"institutionHeld":0,"latestPrice":53.655,"committee":-0.111111,"eps":0,"divideRate":0.012161,"volume":9263,"delay":0,"ttmEps":0,"open":54.5499,"prevYearClose":38.56,"prevWeekClose":53.2941,"prevMonthClose":53.05,"prevQuarterClose":52.6861,"fiveDayClose":55.15,"twentyDayClose":51.193,"sixtyDayClose":40.9},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBC\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"BBC","amount":0.65544,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Virtus LifeSci Biotech Clinical Trials ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2024-12-20","symbol":"BBC","amount":0.23947,"announcedDate":"2024-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-20","defaultRemindTime":1734705000000,"name":"Virtus LifeSci Biotech Clinical Trials ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-27","payableDate":"2024-12-20","currency":"USD","dateTimestamp":1734670800000,"payDate":"2024-12-27"},{"date":"2023-12-20","symbol":"BBC","amount":0.0823,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"Virtus LifeSci Biotech Clinical Trials ETF","recordDate":"2023-12-29","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBC\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-29","value":0.0823,"currency":"USD"},{"executeDate":"2024-12-20","recordDate":"2024-12-20","paymentDate":"2024-12-27","value":0.23947,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-29","value":0.65544,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBC\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660233036","title":"TheraCryf raises £1.05m to advance addiction drug towards Phase 1 trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2660233036","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660233036?lang=en_us&edition=fundamental","pubTime":"2026-08-20 23:18","pubTimestamp":1787239108,"startTime":"0","endTime":"0","summary":"An announcement from Evgen Pharma ( ($GB:TCF) ) is now available. TheraCryf plc has announced a proposed £1.05 million equity raise via a placing a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/theracryf-raises-1-05m-to-advance-addiction-drug-towards-phase-1-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/theracryf-raises-1-05m-to-advance-addiction-drug-towards-phase-1-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660422820","title":"Moderna Stock (MRNA) Soars 133%; Five-Star William Blair Analyst Says Strong Cancer Data Could Be a Game-Changer","url":"https://stock-news.laohu8.com/highlight/detail?id=2660422820","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660422820?lang=en_us&edition=fundamental","pubTime":"2026-08-20 00:16","pubTimestamp":1787156173,"startTime":"0","endTime":"0","summary":"Moderna ($MRNA) skyrocketed 133% on Wednesday after new data from a cancer vaccine Phase 3 trial showed strong results. Today’s gain marks one of t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/moderna-stock-mrna-soars-133-five-star-william-blair-analyst-says-strong-cancer-data-could-be-a-game-changer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/moderna-stock-mrna-soars-133-five-star-william-blair-analyst-says-strong-cancer-data-could-be-a-game-changer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["WDNA","BK4588","MRNA","MRNY","BK4139","BK4551","BK4534","BK4548","BK4501","PSIL","BK4585","BBC","BK4533","BK4532","BK4568","LGHT","IDNA","GNOM","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660422315","title":"Cullinan, Taiho say results of Phase 3 trial selected for presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2660422315","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660422315?lang=en_us&edition=fundamental","pubTime":"2026-08-20 00:10","pubTimestamp":1787155816,"startTime":"0","endTime":"0","summary":"Taiho Oncology and Cullinan Therapeutics (CGEM) announced that results from the planned interim analysis of the Phase 3 REZILIENT3 trial have been ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cullinan-taiho-say-results-of-phase-3-trial-selected-for-presentation-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cullinan-taiho-say-results-of-phase-3-trial-selected-for-presentation-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","CGEM","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660538426","title":"Biodexa recruits 87 of 168 subjects in Serenta Phase 3 eRapa polyposis trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660538426","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660538426?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:36","pubTimestamp":1787146574,"startTime":"0","endTime":"0","summary":"Biodexa Pharmaceuticals (BDRX) announced that it has exceeded the half-way point in the recruitment of subjects in its registrational Phase 3 trial...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biodexa-recruits-87-of-168-subjects-in-serenta-phase-3-erapa-polyposis-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biodexa-recruits-87-of-168-subjects-in-serenta-phase-3-erapa-polyposis-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BBC","BDRX","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660425479","title":"Video: Moderna skyrockets after cancer vaccine shows promise in Phase 3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660425479","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660425479?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:15","pubTimestamp":1787145349,"startTime":"0","endTime":"0","summary":"The Fly has brought its to-the-moment stock market reporting to YouTube! Subscribe if you want to know how the markets will open, which stocks will...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/video-moderna-skyrockets-after-cancer-vaccine-shows-promise-in-phase-3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/video-moderna-skyrockets-after-cancer-vaccine-shows-promise-in-phase-3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660421486","title":"Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP","url":"https://stock-news.laohu8.com/highlight/detail?id=2660421486","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660421486?lang=en_us&edition=fundamental","pubTime":"2026-08-19 20:30","pubTimestamp":1787142600,"startTime":"0","endTime":"0","summary":"August 19, 2026 Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP 87 subjects, over 50% of target, recruited Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” o","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/19/3347617/0/en/biodexa-announces-major-milestone-for-its-serenta-registrational-phase-3-trial-in-fap.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBC","PSIL","PFS","BK4211","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184678054","title":"Patent Cliffs Drive Pharma Expansion as Biotech M&A and IPO Markets Stage a Comeback","url":"https://stock-news.laohu8.com/highlight/detail?id=1184678054","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184678054?lang=en_us&edition=fundamental","pubTime":"2026-08-19 16:15","pubTimestamp":1787127336,"startTime":"0","endTime":"0","summary":"Andy Acker, Portfolio Manager for healthcare and biotech strategies at Janus Henderson Investors, notes that despite interest rates remaining higher than markets anticipated at the start of the year,...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IWO","BK4582","GTPE","BIS","BK4588","BIB","JDOC","BK4585","IBB","PBE","IBBJ","SPCK","MRNX","BBC","FBT","IJT","IAI","IYG","MRNY","QSML","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660499847","title":"Vivoryon Sets Date for 2026 AGM as Kidney Disease Program Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2660499847","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660499847?lang=en_us&edition=fundamental","pubTime":"2026-08-19 01:02","pubTimestamp":1787072575,"startTime":"0","endTime":"0","summary":"Vivoryon Therapeutics AG ( ($NL:VVY) ) has issued an announcement. Vivoryon Therapeutics N.V., a Germany-based clinical-stage biotech listed on Eur...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vivoryon-sets-date-for-2026-agm-as-kidney-disease-program-advances?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vivoryon-sets-date-for-2026-agm-as-kidney-disease-program-advances?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4229","AGM","XBIX","BBC","BK4195","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660461075","title":"Amylyx announces Lucidity Phase 3 trial met primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2660461075","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660461075?lang=en_us&edition=fundamental","pubTime":"2026-08-18 19:06","pubTimestamp":1787051213,"startTime":"0","endTime":"0","summary":"Amylyx (AMLX) Pharmaceutical announced topline results from Lucidity, a 78-participant, multicenter, randomized, double-blind, placebo-controlled P...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amylyx-announces-lucidity-phase-3-trial-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amylyx-announces-lucidity-phase-3-trial-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","AMLX","BBC","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660609102","title":"argenx’s VYVGART Hytrulo hits Phase 3 myositis goal in high‑need IMNM and DM","url":"https://stock-news.laohu8.com/highlight/detail?id=2660609102","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660609102?lang=en_us&edition=fundamental","pubTime":"2026-08-17 13:39","pubTimestamp":1786945177,"startTime":"0","endTime":"0","summary":"arGEN X ( ($GB:0QW0) ) has shared an announcement. argenx has reported positive topline results from its ALKIVIA Phase 3 trial of VYVGART Hytrulo i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/argenxs-vyvgart-hytrulo-hits-phase-3-myositis-goal-in-highneed-imnm-and-dm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/argenxs-vyvgart-hytrulo-hits-phase-3-myositis-goal-in-highneed-imnm-and-dm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SOCL","IMNM","PSIL","BBC","BK4139","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660410575","title":"Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660410575","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660410575?lang=en_us&edition=fundamental","pubTime":"2026-08-17 08:50","pubTimestamp":1786927814,"startTime":"0","endTime":"0","summary":"Mesoblast (MESO) announced that it has completed patient treatment in the MSB-DR004 pivotal randomized controlled Phase 3 trial of rexlemestrocel-L...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mesoblast-completes-patient-treatment-in-msb-dr004-in-phase-3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mesoblast-completes-patient-treatment-in-msb-dr004-in-phase-3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","BK4006","MESO","MSB","BK4139","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660105196","title":"Mesoblast Reaches Pivotal Phase 3 Milestone in Chronic Back Pain Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660105196","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660105196?lang=en_us&edition=fundamental","pubTime":"2026-08-17 08:24","pubTimestamp":1786926259,"startTime":"0","endTime":"0","summary":"Mesoblast Limited ( ($AU:MSB) ) has issued an announcement. Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial testing ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblast-reaches-pivotal-phase-3-milestone-in-chronic-back-pain-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblast-reaches-pivotal-phase-3-milestone-in-chronic-back-pain-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","PSIL","MESO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659199823","title":"BNK Banking Corp Confirms CEO and CFO in Permanent Roles","url":"https://stock-news.laohu8.com/highlight/detail?id=2659199823","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659199823?lang=en_us&edition=fundamental","pubTime":"2026-08-14 08:32","pubTimestamp":1786667549,"startTime":"0","endTime":"0","summary":"The latest announcement is out from BNK Banking Corporation Limited ( ($AU:BBC) ). BNK Banking Corporation Limited has made its interim leadership ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bnk-banking-corp-confirms-ceo-and-cfo-in-permanent-roles?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bnk-banking-corp-confirms-ceo-and-cfo-in-permanent-roles?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659660861","title":"Xencor Advances Dual-Antibody Cancer Trial, Keeping Investor Focus on XNCR","url":"https://stock-news.laohu8.com/highlight/detail?id=2659660861","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659660861?lang=en_us&edition=fundamental","pubTime":"2026-08-14 00:31","pubTimestamp":1786638674,"startTime":"0","endTime":"0","summary":"Xencor Inc. ($XNCR) announced an update on their ongoing clinical study. The Phase 1 trial A Phase 1 Trial, Evaluating the Safety and Tolerability ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/xencor-advances-dual-antibody-cancer-trial-keeping-investor-focus-on-xncr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/xencor-advances-dual-antibody-cancer-trial-keeping-investor-focus-on-xncr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XNCR","BBC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155684243","title":"BofA Securities Boosts Targets on Chinese CXO Players as Strong Biotech Funding Fuels R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=1155684243","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155684243?lang=en_us&edition=fundamental","pubTime":"2026-08-13 12:50","pubTimestamp":1786596641,"startTime":"0","endTime":"0","summary":"BofA Securities has released a report indicating that the Chinese CXO sector is poised to benefit from robust biotech venture capital funding. The bank notes that strong financing in the first half...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBIX","PSIL","IE00BPRC5H50.USD","LU2242644610.SGD","BMED","APXH","LU1251922891.USD","LU1934453819.USD","LU1997245094.SGD","LU1969619763.USD","IBRN","161027","CXO","LU1303224171.USD","SMCO","IE00B5MMRT66.SGD","BBC","IE00B543WZ88.USD","LU0700851271.USD","LU0708995583.HKD","PSCH","SURI","LU2125910500.SGD","LU1997245177.USD","LU2488822045.USD","LU2045819591.USD","02359","MEDI","BK1583","BK1576","LU1046422090.SGD","LU2495084118.USD","IDNA","LU0320764599.SGD","LU0348767384.USD","LU1808992512.USD","BK1141","LU1770034418.SGD","FHLC","LU0348766576.USD","LFSC","LU2328871848.SGD","LU0611395673.USD","LU0456842615.SGD","BK0216","LU1719994722.HKD","603259","LU0052750758.USD","LU1997244956.HKD","LU1979443071.USD","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111112440","title":"Bank of America Securities Raises Targets for Chinese CXO Firms on Strong Biotech Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=1111112440","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111112440?lang=en_us&edition=fundamental","pubTime":"2026-08-13 10:35","pubTimestamp":1786588544,"startTime":"0","endTime":"0","summary":"A report from Bank of America Securities indicates that Chinese CRO/CDMO companies are poised to benefit from robust first-half funding in the global and Chinese biotech sectors, along with active...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","LU0359201612.USD","LU0417516738.SGD","LU1720050803.USD","LU0823426480.USD","LU1997245094.SGD","03759","LU0823426308.USD","LU0979878070.USD","LU1794554557.SGD","LU0708995583.HKD","BK1583","LU1303224171.USD","APXH","IBRN","LU0039217434.USD","LU2125910500.SGD","LU1979443071.USD","LU0516422952.EUR","LU0572944931.SGD","LU1242518931.SGD","BMED","LU1688375341.USD","LU0181495838.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU0327786744.USD","XBIX","LU0140636845.USD","LU0052750758.USD","LU1880383366.USD","LU0417516902.SGD","SMCO","CXO","LU0588546209.SGD","FHLC","SG9999002562.SGD","PSIL","IE00BPRC5H50.USD","LU1251922891.USD","BK1589","LU1046422090.SGD","BBC","02359","603259","LU0456846285.SGD","LU1242518857.USD","LU0700851271.USD","LU0456827905.SGD","LU0516422440.USD","BK0216","LU2039709279.SGD","LU1808992512.USD","LU0359202008.SGD","LU3063872942.SGD","MEDI","LU1934453819.USD","LU2495084118.USD","LU0348825331.USD","BK1576","LU2488822045.USD","LU0029874061.USD","BK1610","BK1141","SG9999002463.SGD","WX","LU1997244956.HKD","LU0128526141.USD","LU2045819591.USD","LU0307460666.USD","LU0456842615.SGD","LU0348735423.USD","SURI","LU0516423091.SGD","02269","LU0348767384.USD","IE00B0JY6N72.USD","LU1969619763.USD","LU2328871848.SGD","BK1521","LU1719994722.HKD","LU0819121731.USD","LU0043850808.USD","LU0051755006.USD","LU0320764599.SGD","LU0326950275.SGD","LU0348766576.USD","LU0516423174.USD","161027","LU0516422366.SGD","IDNA","LU0611395673.USD","LU1997245177.USD","PSCH","LU2242644610.SGD","LU1770034418.SGD","LU0856984785.SGD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659185590","title":"Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659185590","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659185590?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565100,"startTime":"0","endTime":"0","summary":"IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027Ribupatide injection Phase 2b high-dose trial in obesity fully enrolled, dat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/12/3344078/0/en/kailera-reports-second-quarter-2026-financial-results-and-provides-business-updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBC","PSIL","IND","JDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658700929","title":"NeuroThera Labs Wins Japanese Patent for Next-Generation Pain and Fever Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2658700929","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658700929?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:08","pubTimestamp":1786540125,"startTime":"0","endTime":"0","summary":"NeuroThera Labs Inc. ( ($TSE:NTLX) ) has issued an update. NeuroThera Labs Inc., a clinical-stage biotech and majority-owned subsidiary of SciSparc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-wins-japanese-patent-for-next-generation-pain-and-fever-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-wins-japanese-patent-for-next-generation-pain-and-fever-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","XBIX","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908647","title":"Altimmune Announces Second Quarter 2026 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908647","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908647?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:30","pubTimestamp":1786534200,"startTime":"0","endTime":"0","summary":"Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD  $519 million in cash, cas","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/12/3343554/0/en/altimmune-announces-second-quarter-2026-financial-results-and-business-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1978683503.SGD","LU1559883803.SGD","BBC","BK4588","CROC","ALD","ELF","BK4585","LU1242518857.USD","LU0053671581.USD","LU0256863811.USD","PSIL","LU0566484027.USD","LU0979878070.USD","LU0256863902.USD","BK4183","IR","LU1242518931.SGD","LU0417517546.SGD","BK4161","LU0124384867.USD","SG9999001440.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178800852","title":"Youcare Pharmaceutical Subsidiary Receives U.S. FDA Clearance for YKYY033 Injection Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1178800852","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178800852?lang=en_us&edition=fundamental","pubTime":"2026-08-12 16:23","pubTimestamp":1786523005,"startTime":"0","endTime":"0","summary":"Youcare Pharmaceutical Group Co.,Ltd. (688658.SH) announced that its subsidiary, Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd., has recently received notification from the U.S. Food...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BBC","688658"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":2,"totalSize":129,"code":"91000000","status":"200"}]}}